Q-omics provides the consensus-scored IFNWP19 profile across patient tissues and cancer cell-line models. IFNWP19 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, IFNWP19 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IFNWP19 RNA expression shows 14,767 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where IFNWP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNWP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNWP19 survival associations across molecular data types. IFNWP19 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNWP19 RNA expression–survival associations across cancer types. High IFNWP19 expression shows unfavorable associations in LUAD, UCEC, HNSC, UVM, PAAD and LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for IFNWP19 RNA expression.
This table summarizes IFNWP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNWP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNWP19 shows lower tumor expression in KIRC and KICH and higher tumor expression in THCA, HNSC, LUAD and LUSC. The KIRC box plot shows higher IFNWP19 RNA expression in normal versus tumor tissue (log2 FC = −0.983, t-test p < 0.001).
This table shows molecular features associated with IFNWP19 in patient tissues and cancer cell lines. In patient samples, IFNWP19 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
